Amsterdam (1)

Birmingham (1)

Bonn (1)

Bordeaux (1)

Haifa (1)

Jerusalem (1)

London (1)

Lyon (1)

Paris (1)

AGT (1)

PH1 (1)

Primary Hyperoxaluria (1)

RNAi Therapeutic (1)

siRNA (1)

Active, not recruiting (1)

phase 2 (1)

Alnylam Pharmaceuticals (1)

lumasiran (1)

drug (1)

Industry (1)

Interventional (1)

sirna

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Jan 13, 2023